Monoclonal Antibodies
Meeting the Challenges in Manufacturing, Formulation, Delivery and Stability of Final Drug Product
- Publisher's listprice EUR 148.00
-
61 383 Ft (58 460 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 20% (cc. 12 277 Ft off)
- Discounted price 49 106 Ft (46 768 Ft + 5% VAT)
- Discount is valid until: 31 December 2025
Subcribe now and take benefit of a favourable price.
Subscribe
61 383 Ft
Availability
printed on demand
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Elsevier Science
- Date of Publication 23 April 2015
- ISBN 9780081002964
- Binding Hardback
- No. of pages224 pages
- Size 228x152 mm
- Weight 500 g
- Language English 0
Categories
Long description:
Monoclonal antibodies (MAbs) are currently the major class of protein bio therapeutic being developed by biotechnology and pharmaceutical companies. Monoclonal Antibodies discusses the challenges and issues revolving around development of a monoclonal antibody produced by recombinant DNA technology into a therapeutic agent.This book covers downstream processing which includes design of processes to manufacture the formulation, formulation design, fill and finish into closure systems and routes of administration. The characterization of the final drug product is covered where the use of biophysical methods combined with genetic engineering is used to understand the solution properties of the formulation. The latter has become very important since many indications such as arthritis and asthma require the development of formulations for subcutaneous delivery (SC). The development of formulations for IV delivery is also important and comes with a different set of challenges. The challenges and strategies that can overcome these limitations are discussed in this book, starting with an introduction to these issues, followed by chapters detailing strategies to deal with them. Subsequent chapters explore the processing and storage of mAbs, development of delivery device technologies and conclude with a chapter on the future of mAbs in therapeutic remedies.
MoreTable of Contents:
- Introduction: Pharmaceutical Development
- Chapter 1: Current status of monoclonal antibodies in development
- Chapter 2: Stability of mAbs
- Routes of degradation encountered during processing and storage
- Overview of analytical tools used to characterize and monitor stability
- Methods to evaluate in vivo stability
- Chapter 3: Challenges in intravenous (IV) administration
- Chapter 4: Challenges in subcutaneous (SC) administration
- Chapter 5: Strategies to deal with these challenges
- IV strategies
- SC strategies
- Chapter 6: Development of delivery device technology to deal with the challenges of highly viscous mAb formulations at high concentration
- Chapter 7: The molecular basis of high viscosity of mAbs at high concentration
- Chapter 8: Conclusions
- The future of mAbs as Therapeutics
